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Rifampin-resistant meningococcal disease occurred in
a child who had completed rifampin chemoprophylaxis for
exposure to a sibling with meningococcemia. Susceptibility
testing of 331 case isolates found only 1 other case of
rifampin-resistant disease in Minnesota, USA, during 11
years of statewide surveillance. Point mutations in the RNA
polymerase β subunit (rpoB) gene were found in isolates
from each rifampin-resistant case-patient.
C
hemoprophylaxis is recommended for close contacts
of persons with invasive meningococcal disease to
prevent secondary cases. In the 1960s, rifampin replaced
sulfonamides as the recommended agent for chemopro-
phylaxis of household members and other close contacts of
persons with invasive meningococcal disease when sulfon-
amide-resistant meningococci became common (1). In
recent years, ciprofloxacin and ceftriaxone have been
established as acceptable alternatives to rifampin for pro-
phylaxis of meningococcal disease. However, rifampin
remains a popular choice due to its low cost, ease of
administration, and well-established record among infants
and children.
Pharyngeal colonization with rifampin-resistant
meningococci following chemoprophylaxis with rifampin
of persons exposed to meningococcal disease was docu-
mented soon after treatment was initiated (2) and has con-
tinued to be observed over time (3). However, although
rifampin has been used routinely worldwide for more than
30 years, few cases of rifampin-resistant meningococcal
isolates in cases of invasive disease have been reported
(4–7), and reports of only 3 instances in the United States
could be found (8–10).
Rifampin targets the β subunit of DNA-directed RNA
polymerase by inhibiting extension of the RNAstrand. The
β subunit is encoded by the rpoB gene. Previous studies
have demonstrated that one of the mechanisms of rifampin
resistance in Neisseria  meningitidis is associated with sin-
gle point mutations of the rpoB gene that result in amino
acid substitutions (11–13). The data presented in this study
confirm the rapid development of rifampin resistance upon
exposure of meningococci to rifampin as a result of point
mutations in the rpoB gene.
The Study
Cases of invasive meningococcal disease in Minnesota
residents are required to be reported to the Minnesota
Department of Health (MDH). Laboratories throughout the
state routinely submit isolates from patients with this dis-
ease to the MDH Public Health Laboratory, where they are
serogrouped by slide agglutination (Difco, Detroit, MI,
USA). In 1995, the MDH began routinely testing antimi-
crobial susceptibilities on meningococcal isolates and ret-
rospectively conducted susceptibility testing on all
available meningococcal isolates that had been submitted
since 1993.
Antimicrobial susceptibilities were determined by
using broth microdilution. Panels contained cation-adjust-
ed Mueller-Hinton broth with 2%–5% lysed horse blood
(PML Microbiologicals, Wilsonville, OR, USA) and were
incubated at 35°C in CO2 for 20–24 h. An Etest (AB
Biodisk, Solna, Sweden) was also used for isolates that
demonstrated resistance to further quantify degree of
resistance. MIC breakpoints have recently been estab-
lished by the Clinical and Laboratory Standards Institute
for N. meningitidis (14). An MIC >2 µg/mL is considered
resistant to rifampin. 
Molecular subtyping of the sibling isolates was done by
pulsed-field gel electrophoresis (PFGE) as described pre-
viously (15). The rpoB genes from rifampin-resistant and
rifampin-sensitive isolates (Table 1) were amplified by
polymerase chain reaction and sequenced by using primers
described previously (13). DNA and peptide sequences
were analyzed with BioNumerics (Applied Maths, Austin,
TX, USA) and Vector NTI Suite (InforMax, North
Bethesda, MD, USA).
The first known case of rifampin-resistant invasive
meningococcal disease in Minnesota occurred in 1996. A
5-month-old infant had a clinical syndrome consistent with
meningococcemia. He was hospitalized for 10 days,
received antimicrobial drug therapy, and survived. By
Etest, his serogroup B N. meningitidis isolate had a
rifampin MIC >32 µg/mL. This was a sporadic case with
no apparent links to any other previous or subsequent
cases.
In 2002, fever, vomiting, and irritability developed in a
2-month-old infant, followed 12 hours later by labored
breathing and a generalized rash. She was taken to a clin-
ic where she experienced cardiac arrest and underwent
cardiopulmonary resuscitation. She was transferred to a
nearby emergency room where she died ≈1 hour later.
Meningococcemia was suspected and household members
were given prescriptions for rifampin. Waterhouse-
Friderichsen syndrome was noted on autopsy, and
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 6, June 2005 977
*Minnesota Department of Health, Minneapolis, Minnesota, USAN. meningitidis was isolated from a swab of brain tissue.
Three days after the death of the case-patient and 1 day
after completing a 2-day course of rifampin, a fever and
lethargy developed in the case-patient’s 6-year-old sister.
Blood cultures were obtained and she was hospitalized,
given antimicrobial drug treatment (ceftriaxone), and
observed. No cerebrospinal fluid was collected. Blood
cultures were subsequently positive for N. meningitidis.
She responded to ceftriaxone and continued treatment as
an outpatient after a short hospitalization. Household con-
tacts, along with other close contacts of the 6-year-old
girl, again received chemoprophylaxis. It was recom-
mended that adults be treated with ciprofloxacin and chil-
dren be treated with ceftriaxone because of concerns that
1 or both siblings could have had rifampin-resistant
meningococcal infections. No additional related cases
were identified over the following weeks.
Isolates from both siblings were identified as serogroup
C. The PFGE patterns were indistinguishable and had, in
fact, the most common PFGE pattern seen for that
serogroup in Minnesota. Antimicrobial susceptibility test-
ing showed that the isolate from the case-patient was sus-
ceptible to ceftriaxone, penicillin, chloramphenicol,
ciprofloxacin, and rifampin. The MIC for rifampin was
0.008 µg/mL. The isolate from the 6-year-old patient was
susceptible to the same drugs, except for rifampin, which
had an MIC >1 µg/mL by broth microdilution and an MIC
>32 µg/mL by Etest.
A comparison of the nucleotide sequence of the rpoB
gene of both sibling isolates showed they were identical
except for a single nucleotide change. This change resulted
in a substitution of serine for phenylalanine at amino acid
position 548. This substitution has previously been associ-
ated with rifampin resistance in N. meningitidis (12).
The PFGE subtype of the isolate from the rifampin-
resistant case in 1996 differed from that of the siblings’
isolates. Sequencing of the rpoB gene from this isolate
showed an amino acid substitution of histidine for tyrosine
at position 552. This substitution has also been previously
associated with rifampin resistance in N. meningitidis
(Table 1; MDH97-498) (11,13).
Susceptibility results on meningococcal isolates from
1993 to 2003 for other antimicrobial agents are shown in
Table 2. Using the newly established breakpoints, we
observed that 92% (303/331) of the isolates were suscepti-
ble to penicillin, 100% (205/205) were susceptible to cef-
triaxone, 100% (331/331) were susceptible to meropenem,
100% (205/205) were susceptible to ciprofloxacin, 100%
(331/331) were susceptible to chloramphenicol, and 48%
(158/ 331) were susceptible to trimethoprim-sulfamethox-
azole.
Conclusions
Primary cases of rifampin-resistant meningococcal dis-
ease are rare. While more common, secondary cases with
rifampin resistance can develop following chemoprophy-
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MDH were susceptible to ceftriaxone and ciprofloxacin.
Ceftriaxone must be given parenterally but is the recom-
mended prophylactic agent for infected pregnant women.
According to the 2003 American Academy of Pediatrics
Report of the Committee on Infectious Diseases,
ciprofloxacin may be used by persons >15 years of age.
While few instances of ciprofloxacin resistance have been
reported, its widespread use may result in greater resist-
ance in N. meningitidis (as has occurred in related
pathogens such as Neisseria gonorrhoeae) (16,17).
Persons receiving chemoprophylaxis should be advised
about the potential of meningococcal disease developing,
even though they have taken antimicrobial agents as pre-
scribed. If a close contact who has been treated with
rifampin becomes ill with meningococcal disease, alterna-
tive antimicrobial agents should be used for prophylaxis
until rifampin sensitivity of the secondary infection can be
established. Although rifampin-resistant meningococcal
disease is still rare after 30 years of using rifampin for
chemoprophylaxis and ciprofloxacin resistance has rarely
been observed, susceptibilities to chemoprophylactic
agents should be monitored to ensure that recommenda-
tions are sufficiently effective to minimize the occurrence
of secondary cases.
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